[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100229052":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":51,"collaborators":29,"id":55,"slug":29,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":17,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":29,"studyType":66,"phases":67,"briefSummary":70,"conditions":71,"keywords":29,"overallStatus":37,"whyStopped":29,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"anti-CD30 CAR T cells","EXPERIMENTAL","Patients receive CART30 cell infusions with an escalation dose.",[13],"Biological: CART30",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","CART30","Cells will be infused 1 day after the completion of conditioning regimen.",[9],[9],[22],{"name":23,"affiliation":5,"role":24},"Weidong Han, Ph.D","STUDY_CHAIR",[26,31],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","86-10-66937463",null,"hanwdrsw@sina.com",{"name":32,"role":27,"phone":33,"phoneExt":29,"email":34},"Quanshun Wang, Ph.D","86-10-66939486","wqs63@sohu.com",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Beijing","Beijing Municipality","100853","China",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49,50],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},{"name":32,"role":27,"phone":33,"phoneExt":29,"email":34},{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Han weidong","Director","100229052",false,"NCT02259556","CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas","Inclusion Criteria:\n\n* Male and female subjects with CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma relapsing after autologous stem-cell transplantation (ASCT), or refractory to 2 multidrug regimens and\u002For anti-CD30 antibody treatment.\n* Newly diagnosed CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma patients who are unable to receive or complete standard chemotherapy.\n* Karnofsky or Lansky score greater than 60%.\n* Expected survival\\>12 weeks.\n* Creatinine\\\u003C2.5mg\u002Fdl.\n* ALT (alanine aminotransferase)\u002FAST (aspartate aminotransferase)\\\u003C3 fold normal.\n* Bilirubin\\\u003C2.5mg\u002Fdl.\n* Pulse oximetry of \\>90% on room air.\n* Adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of expected corrected for hemoglobin.\n* Available autologous T cells with 10% or more expression of CD30 CAR determined by flow-cytometry.\n* Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form.\n\nExclusion Criteria:\n\n* Active infection such as hepatitis B or C.\n* Receive anti-CD30 antibody-based therapy within recent 6 weeks.\n* Current use of systemic corticosteroids.\n* Pregnant or lactating.\n* Confirmed tumor in pulmonary and archenteric tissues.","ALL","16 Years","80 Years",{"count":64,"type":65},30,"ESTIMATED","INTERVENTIONAL",[68,69],"PHASE1","PHASE2","Chimeric antigen receptor-modified T cells (CART) holds great promise for treatment of tumors. In this trial, CD30 positive Hodgkin's lymphoma and Non-Hodgkin's lymphoma will be treated by CD30-specific CART cells (CART30).",[72,73],"Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma","2016-01-26",{"date":76,"type":65},"2016-01-28",{"date":78,"type":29},"2014-10",{"date":80,"type":65},"2029-10",{"name":5,"class":6},1]